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Obstructive lung function in sarcoidosis may be missed, especially in older white 
patients 
 
To the Editors: 
Lung function abnormalities are often present when patients are first diagnosed with pulmonary sarcoidosis, and most 
studies to date indicate that the predominant pattern is of restriction or normal airways, with a truly obstructive pattern 
in a minority [1]. The largest case–control study of sarcoidosis to date, the ACCESS (A Case Control Etiologic Study of 
Sarcoidosis) trial, showed that the biggest group of patients in that particular cohort (46.9%) presented with a forced 
expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio of .80% and only 13.2% presented with a ratio of 
50–69% [2]. Of the 215 patients from the ACCESS trial who were followed up for a further 2 yrs, the majority showed 
no change in pulmonary function, radiographic stage or dyspnoea score [3]. A more recent European study showed that 
patients with sarcoidosis had impaired lung compliance and a reduced diffusing capacity of the lung for carbon 
monoxide (DL,CO) and, while there was no predominance of restrictive lung defects, airway obstruction was only 
present in 11.7% of patients [4]. 
Over the past 3 yrs, we have noticed that an increasing number of patients who present to our clinics in West London, 
UK with a new diagnosis of pulmonary sarcoidosis have a predominantly obstructive lung defect. A detailed analysis of 
lung function in sarcoidosis with respect to stratification by patient demographics has, to our knowledge, not been 
previously reported. We present the results of a systematic retrospective analysis of 164 consecutive patients presenting 
with a new diagnosis of pulmonary sarcoidosis over a 10-yr period and in whom formal lung function was recorded at 
the time of presentation. All patients had a clinically definite diagnosis, with supportive histology where available, and 
the subsequent follow-up examinations were in keeping with the original diagnosis. Lung function testing was carried 
out using a standardised protocol (single-breath method for gas transfer and nitrogen washout for lung volumes) and 
recorded electronically. All testing was performed at a single institution and statistical comparisons were performed by 
Mann–Whitney U-tests and multiple linear regression analysis. 
Our data show that the percentage of patients presenting with an obstructive lung defect of FEV1/FVC ratio 50–69% was 
higher than expected, at 23.2% (fig. 1a), while 42.1% of patients presented with FEV1/FVC .80%. There was no 
significant difference in smoking status (the majority were nonsmokers), diagnosis of asthma or chronic obstructive 
pulmonary disease (COPD) between the obstructive and restrictive groups. We also found that patients with an 
obstructive defect (median 53.5 yrs, interquartile range (IQR) 39–61.25 yrs) were significantly older (p50.0015) than 
those with restrictive defects (median 44 yrs, IQR 33–50.5 yrs) (fig. 1b). 
A significant difference (p50.028) was found in lung function between the main ethnic groups, with black patients 
having a higher FEV1/FVC ratio (median 81%, IQR 73–85%) than white patients (median 78%, IQR 69–83%). In 
addition, the proportions of lung function pattern within ethnicities was dramatically different (fig. 1c). White patients 
(n583) presented with a restrictive/obstructive ratio of 1.4, while this ratio was more than twice as large in black 
patients (n554), at 4.0. The ratio of Asian (Indian subcontinent) patients (n527) was similar to that in the white 
population, at 1.3. There was no difference found between the ethnicities in terms of other measured lung function 
parameters, including the DL,CO % predicted (fig. 1d), residual volume or FVC. 
On multivariate analysis of the black patient group (online supplementary table 1), there were no significant 
demographic or clinical associations found, suggesting that the greater proportion of black patients seen presenting 
with a restrictive lung pattern in this cohort was not due to factors such as presence of co-existing lung disease or 
demographic differences (e.g. 5.6% of black patients and 6% of white patients were recorded as having asthma or 
COPD at the time of diagnosis of sarcoidosis). Only a small number of patients with obstructive lung defects were 
assessed for bronchodilator response, but in those who were (n59), we saw no significant improvement in lung function 
(mean change in FEV1 5%, range -8–13%). 
Almost one in four of all patients in this cohort presented with an FEV1/FVC ratio of 50–69% and this obstructive 
pattern of lung function was significantly more common in those who were older and who were white. One possible 
explanation for our findings of a larger than expected group with significant airway obstruction may be our routine use 
of endobronchial ultrasound sampling for lymph node disease. This relatively specialised method, with greater 
diagnostic sensitivity in sarcoidosis [5], may be providing a histological confirmation in patients in whom a diagnosis  
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Figure 1. a) In this cohort, 23.2% of patients with pulmonary sarcoidosis presented with a forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio of 
50–69%. b) The median age of patients with obstructive lung disease at presentation was significantly higher (53.5 yrs) than that of those with restrictive disease (44 
yrs). c) The ratio of restrictive/obstructive lung function at first presentation differed within ethnic groups, with black patients displaying a higher ratio (4.0) than 
white patients (1.4). Other measures of lung function did not differ between ethnic groups, including diffusing capacity of the lung for carbon monoxide (DL,CO) % 
predicted (% pred), residual volume and FVC. #: p50.0015. 
 
of obstructive airway disease may otherwise have been made. Indeed, there are numerous published case reports of 
patients with obstructive bullous lung disease in whom the underlying diagnosis of sarcoidosis has been originally 
missed [6]. 
These data are the first to stratify lung function in sarcoidosis by patient demographics, but we cannot fully explain the 
significantly higher median age at presentation found in patients with obstructive disease. There is some evidence to 
suggest that the FEV1 reduces as individuals get older, by as much as 6–8% per decade [7], and an FEV1 that declines at 
a faster rate than the FVC might help explain our findings in part, but is unlikely to represent the entire difference seen. 
The different ratios of restrictive/obstructive disease seen between ethnic groups may be partly explained by ethnic 
differences in baseline lung function in healthy populations [7], but our data are contrary to the only previously 
published work in this area, which showed that the predominant airway disease in a cohort of African-Americans with 
sarcoidosis was one of obstruction, rather than restriction [8]. Our findings may in part be due to differences in ethnic 
lineage, with a greater percentage of descendants from the West Indies making up the UK black population compared 
to that seen in the USA [9]. 
The clinical course of sarcoidosis is often more severe in black patients [10] and the recent definition of clinical 
phenotypes by the World Association of Sarcoidosis and Other Granulomatous Diseases showed that African-American 
patients were likely to have a higher clinical outcome status, indicating more chronic disease [11]. Less than 10% of the 
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patients classified as black in the present study had self-declared as being of mixed race, which should not, therefore, 
have affected the outcome and our findings of a higher incidence of restrictive airways disease in black European patients 
need to be investigated further. Notably, accurate chest radiographic staging was not available for all patients, but we do 
not feel that this has affected the interpretation of our results, as there was no association found between the presence of 
lung fibrosis and black ethnicity on multivariate analysis (online supplementary table 1). Additionally, chest 
radiographic staging may be interpreted differently, even between expert radiologists, and there is no evidence to date 
for a relationship between airway obstruction and radiographic stage in sarcoidosis [8]. 
We believe that our study is the first to identify different proportions of obstructive and restrictive airway disease between 
the main ethnic groups in sarcoidosis, and also the first to report an association of functional impairment with age. 
Despite a weak evidence base, sarcoidosis patients are often prescribed inhaled corticosteroids and b-agonists for 
respiratory symptoms regardless of their pattern of lung function at presentation [12]. Large airway obstruction in 
sarcoidosis is associated with increased mortality [13] and our data suggest that these patients may represent an under-
diagnosed group. Further studies are needed to confirm these demographic associations, as well as to assess disease 
progression and response to inhaled therapies in this particular clinical phenotype of sarcoidosis. 
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